The 70-Gene Prognostic Signature for Korean Breast Cancer Patients.
- Author:
Kuk Young NA
1
;
Ku Sang KIM
;
Jeong Eon LEE
;
Hee Jeong KIM
;
Jung Hyun YANG
;
Sei Hyun AHN
;
Byung In MOON
;
Ra Mi KIM
;
Si Mon KO
;
Yong Sik JUNG
Author Information
- Publication Type:Validation Studies ; Original Article
- Keywords: Breast neoplasms; Gene expression profiling; Korea
- MeSH: Asian Continental Ancestry Group; Breast; Breast Neoplasms; Diagnostic Tests, Routine; Europe; Follow-Up Studies; Gene Expression Profiling; Genes, vif; Humans; Incidence; Korea; National Institutes of Health (U.S.); Prognosis
- From:Journal of Breast Cancer 2011;14(1):33-38
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: A 70-gene prognostic signature has prognostic value in patients with node-negative breast cancer in Europe. This diagnostic test known as "MammaPrint(TM) (70-gene prognostic signature)" was recently validated and implementation was feasible. Therefore, we assessed the 70-gene prognostic signature in Korean patients with breast cancer. We compared the risk predicted by the 70-gene prognostic signature with commonly used clinicopathological guidelines among Korean patients with breast cancer. We also analyzed the 70-gene prognostic signature and clinicopathological feature of the patients in comparison with a previous validation study. METHODS: Forty-eight eligible patients with breast cancer (clinical T1-2N0M0) were selected from four hospitals in Korea. Fresh tumor samples were analyzed with a customized microarray for the 70-gene prognostic signature. Concordance between the risk predicted by the 70-gene prognostic signature and risk predicted by commonly used clinicopathological guidelines (St. Gallen guidelines, National Institutes of Health [NIH] guideline, and Adjuvant! Online) was evaluated. RESULTS: Prognosis signatures were assessed in 36 patients. No significant differences were observed in the clinicopathological features of patients compared with previous studies. The 70-gene prognosis signature identified five (13.9%) patients with a low-risk prognosis signature and 31 (86.1%) patients with a high-risk prognosis signature. Clinical risk was concordant with the prognosis signature for 29 patients (80.6%) according to the St. Gallen guidelines; 30 patients (83.4%) according to the NIH guidelines; and 23 patients (63.8%) according to the Adjuvant! Online. Our results were different from previous validation studies in Europe with about a 40% low-risk prognosis and about a 60% high-risk prognosis. The high incidence in the high-risk group was consistent with data in Japan. CONCLUSION: The results of 70-gene prognostic signature of Korean patients with breast cancer were somewhat different from those identified in Europe. This difference should be studied as whether there is a gene disparity between Asians and Europeans. Further large-scale studies with a follow-up evaluation are required to assess whether the use of the 70-gene prognostic signature can predict the prognosis of Korean patients with breast cancer.
